Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
Phase 1
138
about 3.2 years
18+
4 sites in CT, NC, TX
What this study is about
This trial is testing a new treatment called M7437 for people with advanced solid tumors. The goal of this first-in-human (FIH) study is to see if M7437 is safe, well-tolerated, and has some activity against the cancer cells that express Ly6E.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take M7437
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Dose-escalation Cohort: Number of Participants With Treatment-Emergent Adverse Event (TEAEs) and Adverse Event (AEs)
Secondary: Dose-escalation Cohort: Overall Response (OR) According to Response Evaluation Criteria inSolid Tumor (RECIST) version 1.1 criteria as Assessed by Investigator